BrightSpring Health Services, Inc. BTSG R2KR3KPHARMA
Company Overview
BrightSpring Health Services, Inc. operates as a home and community-based healthcare services platform in the United States. The company operates through two segments, Pharmacy Solutions and Provider Services. Its platform focuses on delivering pharmacy and provider services, including clinical and supportive care in home and community settings to Medicare, Medicaid, and insured populations. It also offers infused, injectable, and oral medication services; and patient-centric, highly skilled, and compassionate clinical home health care, as well as rehabilitation services, including physical, speech and occupational therapy and applied behavioral analysis. The company was formerly known as Phoenix Parent Holdings Inc. and changed its name to BrightSpring Health Services, Inc. in May 2021. BrightSpring Health Services, Inc. was founded in 1974 and is headquartered in Louisville, Kentucky.
Why Investors Should Care
Revenue has grown at a 18.7% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $12.91B (+28.2% YoY); net profit $190.67M.
- Trailing 12 Months Year-on-year growth — revenue +23.0%, earnings +196.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 18.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 18.69% |
| 1 Year: | 23.00% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 196.60% |
Stock Price Performance
| 1 Year: | +171.24% |
| 6 Months: | +46.37% |
| 3 Months: | +5.80% |
| 1 Month: | +0.21% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)48.21 · Neutral
P/E of 54.22 is above the sector median of 25.17 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 18.7% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 54.2.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BTSG BrightSpring Health Services, Inc. R2KR3KPHARMA | 60.73 | 54.22 | $12.02B | 0.00% | 6.47% | 13.04% | 18.69% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.03B | 2.17B | 2.26B | 2.29B | 2.44B | 2.60B | 2.88B | 3.15B | 3.33B | 3.61B |
| Gross Profit | 334.71M | 372.07M | 358.30M | 292.49M | 312.18M | 323.09M | 338.37M | 374.85M | 392.01M | 482.22M |
| Operating Income | 51.55M | 79.62M | -52.25M | -15.34M | 38.65M | 29.10M | 50.74M | 48.56M | 87.84M | 121.45M |
| Net Income | -21.38M | 3.99M | -130.67M | -45.75M | 19.92M | -8.23M | 29.54M | 28.21M | 55.84M | 148.77M |
| Diluted EPS | -0.18 | 0.03 | -1.11 | -0.26 | 0.10 | -0.04 | 0.14 | 0.13 | 0.26 | 0.67 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 7.72B | 7.69B | 10.07B | 12.91B |
| Gross Profit | 1.35B | 1.14B | 1.27B | 1.52B |
| Operating Income | 187.83M | 58.12M | 107.95M | 295.25M |
| Net Income | -53.91M | -154.60M | -18.06M | 190.67M |
| Diluted EPS | -0.46 | -1.31 | -0.09 | 0.87 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | - | 5.53B | 5.93B | 6.41B |
| Total Equity | 774.82M | 754.78M | 584.74M | 1.65B | 1.88B |
| Cash & Equivalents | - | - | 13.07M | 60.95M | 88.37M |
| Long Term Debt | - | - | 3.33B | 2.56B | 2.46B |
| Total Liabilities | - | - | 4.92B | 4.27B | 4.53B |
| Current Liabilities | - | - | 1.25B | 1.43B | 1.85B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -4.65M | 210.78M | 23.77M | 490.17M |
| Investing Cash Flow | 45.36M | -134.43M | -140.24M | -305.08M |
| Financing Cash Flow | -73.81M | -76.91M | 164.65M | -157.87M |
| Capital Expenditure | -70.11M | -73.53M | -80.91M | -95.48M |
| Free Cash Flow | -74.77M | 137.26M | -57.14M | 394.69M |
| Share Buybacks | - | 650.00K | 650.00K | 43.17M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 17.5% | 14.8% | 12.6% | 11.8% |
| Operating Margin % | 2.4% | 0.8% | 1.1% | 2.3% |
| Net Margin % | -0.7% | -2.0% | -0.2% | 1.5% |
| ROE % | -7.1% | -26.4% | -1.1% | 10.2% |
| ROCE % | - | 1.4% | 2.4% | 6.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Kohlberg Kravis Roberts & Co. L.P. | 13.56% | 26.83M | $1.59B |
| 2 | Blackrock Inc. | 12.14% | 24.03M | $1.42B |
| 3 | FMR, LLC | 6.77% | 13.39M | $791.94M |
| 4 | Invesco Ltd. | 6.04% | 11.94M | $706.13M |
| 5 | Vanguard Portfolio Management LLC | 5.03% | 9.95M | $588.13M |
| 6 | Price (T.Rowe) Associates Inc | 5.00% | 9.90M | $585.32M |
| 7 | Vanguard Capital Management LLC | 3.70% | 7.31M | $432.39M |
| 8 | State Street Corporation | 3.17% | 6.26M | $370.35M |
| 9 | T. Rowe Price Investment Management, Inc. | 3.05% | 6.04M | $357.26M |
| 10 | Geode Capital Management, LLC | 2.62% | 5.18M | $306.48M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BTSG
BrightSpring Health Services (BTSG) Stock Still Looks Stretched Following Raised Outlook - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxQOG4yYW04NVZVbEpXUk9WX3BtMVNqSFJaQWlvVTBoX3F0LUdTZXZFMHNVODRpZFFfaTdVVGtKMTZBWV9lMmRfbG1XZkg0X0ozTGNzaEZ2RU5fTVFOcDRJUjZ3NnRIU2l3MVA0OXVKUl9VakxXRHBneUY1cnJPeFliaUJCQ2o2aDhFYm1PY0…
$BTSG stock is down 15% today. Here's what we see in our data. - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNRW5KTE4wNkVCdEtJQUtRYjJCdlVlN2U0b1A5aEwyeTUzTWZHc21ESndURGdBSnd4SVJLTTNsWU41dUV1SFN3VVBLcm5DOGV1VkJfNXk3a2N4aUNMMEhMdVBFSzhrLUU4WVpmcDBkUG9fRmxiTWJYNmdhU2ZORzZNV1dqdFBEMjZYR0MwcE…
The Technical Signals Behind (BTSG) That Institutions Follow - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxNZV9XemduMnZubVRERHNsSTRHRkZVQUdVZ1dNbTNGXzhPYnA4d2pHYlFXS0JUamdaLU93T3BhM1ZoT3h1YVVucENzVVZ3dXFnYzVxWmdPQWxZdnpvWHZNcnpCbUkxLW1hWHN2Yi01TzFicWV1TjU4X19UX1hRNDloU2FpWUdYYXF6REdiOU…
BrightSpring Health Services (BTSG) Stock Retreats As Valuation Angst Trumps Growth - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxNTGZTVkpHRDFCOUplQlJnbzBzVW1PSTBuSlMxUDFDSEN1TlBFVWpYR0JJU1lKN3lzMmJUdE1nMkItdm5nVmx1dmtER1JkdXZDWEZKZDVWLVR1bFV6T3pNdE5BMUlOQl9UV1REN0xnZ1RFVy1yV2ZKbW53OUVUblMwM1V6cHFYNUtoU1hqcU…
BrightSpring Health Services (NASDAQ:BTSG): High Growth Momentum Stock Flashing a Breakout Setup - ChartMill
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxOMkN3bVNKTDlnMHVESXFva0tLd3R1MkNCNlB5c3ZESTd2NWN3RHRnbVJ0UWNPMzBWdVdPdlRXaEJDdHFVZUhNb2VfTzNzS2hrSkFaWFdoN0lCNWQ4amlDXzlOVlVOR2dEVmtXdnlSX1IwUk5xZzFyRGQybjhEbW12Vy0yUGw4M2c3QzZSY3…
BrightSpring pays down $300M debt as adjusted EBITDA reaches $206M - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxQWlV4QmNMV1BkMzVuYUQyLWIyeGNudHJOZXl1XzhISWpSaVRXbGRLZUt3S2JfbC15TVNVSFMwdlBJd0I0TlNlVnZPd3JSR2NiOVlBLXE2elJmOV9qb294bVNKVlNjRUlEQnFUWTZWZTcxbGVaSGlGdGpOdTdWT3BGWWNIMWRTLU9EMGdMdX…
BTSG — Frequently Asked Questions
What is the current share price of BrightSpring Health Services, Inc. (BTSG)?
As of 2026-09-07 16:24 PDT, BrightSpring Health Services, Inc. (BTSG) trades at $60.73 on NasdaqGS. Its 52-week range is $22.39 to $72.91.
What is the market capitalisation of BTSG?
BrightSpring Health Services, Inc. (BTSG) has a market capitalisation of $12.02B on NasdaqGS.
What is the P/E ratio of BTSG?
BTSG trades at a trailing price-to-earnings (P/E) ratio of 54.22. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 6.21.
What is the return on equity (ROE) of BTSG?
BTSG has a return on equity (ROE) of 13.04%. Its return on capital employed (ROCE) is 6.47%.
Is BTSG a good stock to buy?
This page provides a data-driven analysis of BrightSpring Health Services, Inc. (BTSG), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.